<?xml version="1.0" encoding="UTF-8" standalone="no"?>
<ibecs-document>
<record>
<header>
<identifier>ibc-146713</identifier>
<setSpec>2253-654X</setSpec>
</header>
<metadata xmlns="http://example.org/myapp/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://example.org/myapp/schema.xsd">
<dc:title xml:lang="en">Mild to moderate increase of serum calcitonin levels only in presence of large medullary thyroid cancer deposits</dc:title>
<dc:description xml:lang="en">Many open questions remain to be elucidated about the diagnosis, treatment and prognosis of medullary thyroid cancer (MTC). The most intriguing concerns the outcome of MTC patients after surgery. Great importance is usually given to serum calcitonin (Ct) and carcinoembryonic (CEA) levels. It is commonly believed that the higher are the levels of these tumor markers and their kinetics (double time and velocity of markers levels) the worst is the prognosis. However, this is not the rule, as there are huge MTC metastatic deposits characterized by low serum Ct and CEA levels, and this condition is not closely related to the outcome of the disease during post-surgical follow-up. A series is reported here of patients who have these characteristics, as well as a description of their prognosis and clinical outcome (AU)</dc:description>
<dc:creator>Torresan, F</dc:creator>
<dc:creator>Rubello, D</dc:creator>
<dc:creator>Vinjamury, S</dc:creator>
<dc:creator>Pelizzo, MR</dc:creator>
<dc:creator>Perkins, AJ</dc:creator>
<dc:creator>Chondrogiannis, S</dc:creator>
<dc:creator>Colletti, PM</dc:creator>
<dc:creator>Rampin, L</dc:creator>
<dc:creator>Roit, A da</dc:creator>
<dc:creator>Merante Boschin, I</dc:creator>
<dc:language>en</dc:language>
<dc:description xml:lang="es">Numerosas preguntas están pendientes de responder sobre el diagnóstico, tratamiento y pronóstico del cáncer medular de tiroides (MTC). El problema más intrigante se refiere a la evolución de los pacientes después de la cirugía. Por lo general, una gran importancia se le da a la calcitonina sérica (Ct) y los niveles de antígeno carcinoembrionario (CEA). Está ampliamente aceptado que cuanto mayor sean los niveles de estos marcadores tumorales y su cinética (tiempo de duplicación de los niveles), peor será el pronóstico. Sin embargo esta no es una regla: pueden existir grandes depósitos metastásicos de MTC que se acompañan de niveles bajos de Ct y CEA, y esta condición no está estrechamente relacionada con la evolución de la enfermedad durante de seguimiento postoperatorio. Presentamos una serie de pacientes con estas características y describimos su pronóstico y evolución clínica (AU)</dc:description>
<dc:source>Rev. esp. med. nucl. imagen mol. (Ed. impr.);34(6): 378-382, nov.-dic. 2015. ilus</dc:source>
<dc:identifier>ibc-146713</dc:identifier>
<dc:title xml:lang="es">Niveles séricos moderadamente elevados de calcitonina en presencia de grandes lesiones de cáncer medular de tiroides</dc:title>
<dc:subject>^d10421^s29166</dc:subject>
<dc:subject>^d1884^s29166</dc:subject>
<dc:subject>^d8374^s22074</dc:subject>
<dc:subject>^d21012</dc:subject>
<dc:subject>^d21034</dc:subject>
<dc:subject>^d21030</dc:subject>
<dc:subject>^d21044</dc:subject>
<dc:subject>^d22372</dc:subject>
<dc:subject>^d20174</dc:subject>
<dc:subject>^d22696^s29166</dc:subject>
<dc:subject>^d35393</dc:subject>
<dc:subject>^d12823^s22053</dc:subject>
<dc:subject>^d12823^s29166</dc:subject>
<dc:subject>^d23568</dc:subject>
<dc:subject>^d22372^s22044</dc:subject>
<dc:subject>^d9062</dc:subject>
<dc:subject>^d33478</dc:subject>
<dc:subject>^d33478^s22022</dc:subject>
<dc:subject>^d9555^s29166</dc:subject>
<dc:type>article</dc:type>
<dc:date>201512</dc:date>
</metadata>
</record>
</ibecs-document>
